Gefitinib, a first-line tyrosine kinase inhibitor for advanced EGFR-mutant non-small-cell lung cancer (NSCLC), effectively suppresses EGFR-mediated oncogenic signaling [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.